Ganciclovir prophylaxis of cytomegalovirus disease

Transplant Proc. 1997 Feb-Mar;29(1-2):804-6. doi: 10.1016/s0041-1345(96)00141-8.

Authors

D J Conti¹, G Shen, T Singh, A Isenberg, B M Freed

Affiliation

¹ Department of Surgery, Albany Medical College, New York 12208, USA.

PMID: 9123534
DOI: 10.1016/s0041-1345(96)00141-8

No abstract available

Publication types

Clinical Trial
Controlled Clinical Trial

MeSH terms

Adult
Antiviral Agents / economics
Antiviral Agents / therapeutic use*
Costs and Cost Analysis
Cytomegalovirus Infections / epidemiology
Cytomegalovirus Infections / prevention & control*
Drug Therapy, Combination
Female
Ganciclovir / economics
Ganciclovir / therapeutic use*
Graft Rejection / therapy
Graft Survival
Humans
Immunosuppressive Agents / therapeutic use
Kidney Transplantation* / immunology
Male
Muromonab-CD3 / therapeutic use
New York
Postoperative Complications / prevention & control*
Risk Factors
Survival Rate

Substances

Antiviral Agents
Immunosuppressive Agents
Muromonab-CD3
Ganciclovir